NanoEcho AB has signed a new letter of intent with us4us Ltd. regarding continued collaboration on the product development that was initiated with a letter of intent in July 2022. The collaboration is focused on the development of the next-generation ultrasound scanner module.
The basic patent for NanoEcho’s method, previously granted in Japan, Europe, and South Korea, has now been approved also in Canada. The basic patent protects the performance of a hand-held probe with the unique combination of placing an ultrasound transducer together with one or more magnets on the same device. The same patent is under examination in the United States, where the process proceeds according to plan.
An investigator-led clinical development study has started at Skåne University Hospital in Malmö. In this context, the first examination of resected rectal cancer tissue has been performed with the NanoEcho diagnostic system.
At his own request, BG (Bengt-Göran) Svensson has chosen to leave NanoEcho’s board for medical reasons. At the same time, he announces that he is leaving all of his board assignments.
NanoEcho and SPL medical have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for the iron-oxide based nanoparticle. The aim of the collaboration is to achieve market approval for the NanoEcho indication, diagnostics of rectal cancer lymph node metastases.
NanoEcho has been cleared to start a clinical development study at Skåne University Hospital in Malmö. The ethics committee has already approved the study and recruitment of patients is planned to commence during the fall.
NanoEcho has chosen the supplier us4us and started collaboration around the development and future manufacturing of the imaging device.
NanoEcho has chosen the supplier Vermon SA, and started cooperation for the development and future manufacturing of the ultrasound transducer.